Related Experiment Videos
Endoscopic therapy of sclerosing cholangitis
J G Lee1, S M Schutz, R E England
1Department of Medicine, Duke University Medical Center, Durham, NC.
Hepatology (Baltimore, Md.)
|March 1, 1995
Summary
Endoscopic treatment for primary sclerosing cholangitis (PSC) shows promising results. A majority of patients experienced symptom improvement, better liver function, and positive cholangiographic changes after procedures like dilation and stenting.
Area of Science:
- Gastroenterology
- Hepatology
- Interventional Endoscopy
Background:
- Primary sclerosing cholangitis (PSC) is a chronic liver disease with limited treatment options.
- The role of endoscopic interventions in managing PSC remains incompletely defined.
Purpose of the Study:
- To evaluate the efficacy and outcomes of endoscopic treatment in patients with primary sclerosing cholangitis.
- To assess clinical symptoms, liver function tests, and cholangiographic findings post-intervention.
Main Methods:
- Retrospective analysis of 53 consecutive PSC patients undergoing therapeutic endoscopic procedures (1986-1993).
- Data abstracted from GI-TRAC database, medical records, and cholangiograms.
- Clinical follow-up via telephone interview assessing symptoms, liver function, and cholangiograms.
Main Results:
- High technical success rates for dilations (43/50), stentings (37/38), nasobiliary tubes (8/8), and stone extractions (11/17).
- Significant improvement in liver function tests (P < .001) within 3 months post-treatment.
- Overall, 77% of patients (41/53) showed improvement in symptoms, liver function, or cholangiograms.
Conclusions:
- Endoscopic interventions, including dilation and stenting, can lead to significant clinical improvement in patients with primary sclerosing cholangitis.
- Therapeutic ERCP offers a viable option for managing complications and improving outcomes in PSC.
- Further research is warranted to establish definitive endoscopic treatment guidelines for PSC.